On July 10, 2025, the U.S. Food and Drug Administration (FDA) announced publication of over 200 complete response letters (CRLs) issued in response to applications submitted to FDA for approval of drugs or biologics between...more
On June 11, 2025, the Delaware Court of Chancery found Alexion Pharmaceuticals liable for more than $180 million in damages to former stockholders of Syntimmune, Inc., following the Court’s September 2024 ruling that Alexion...more
6/19/2025
/ Biotechnology ,
Breach of Contract ,
Clinical Trials ,
Commercially Reasonable Efforts ,
Contract Disputes ,
Contract Terms ,
Damages ,
Life Sciences ,
Merger Agreements ,
Mergers ,
Pharmaceutical Industry
Summary of 2021 Trends, Themes, and Takeaways -
We are proud to present our sixth annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against...more